MeMed Diagnostics has developed and validated an immune-based protein signature, MeMed BV, which distinguishes between bacterial and viral infections, providing a powerful tool in the fight against resistant strains of bacteria.An ELISA format of MeMed BV called ImmunoXpert is cleared for use in the EU (CE-IVD), Switzerland, and Israel and is currently in pilot distribution in these areas.MeMed is also developing MeMed Key, a platform that paves the way for measuring multiple proteins and signatures, both conventional and innovative, with central lab precision at the point of care.

MeMed Key will measure MeMed BV within minutes.In September 2021, the company was granted 510(k) clearance by the FDA for MeMed BV for adults and children.